基石药业(02616.HK)CS1001-101临床研究摘要已获ESMO2019年年会接受以海报形式展示
格隆汇8月16日丨基石药业(02616.HK)宣布,公司正在进行中的CS1001-101Ib期临床研究相关摘要,已于近期被即将召开的欧洲肿瘤学会("ESMO")2019年年会接受,并将通过海报形式展示。
CS1001是由基石药业开发的在研抗PD-L1单克隆抗体,也是公司三款肿瘤免疫治疗骨干(backbone)产品之一。目前一系列评估CS1001的临床试验正于中国开展,其中包括针对多个癌种的一项多臂Ib期试验,两项注册性II期试验和三项III期试验。
CS1001-101是一项Ia/Ib期、开放性、多剂量给药的剂量探索和扩展研究,旨在评估CS1001对於晚期实体瘤或淋巴瘤患者的安全性、耐受性、药代动力学特徵和抗肿瘤疗效。目前试验已圆满完成剂量爬坡。在美国临床肿瘤学会2019年年会上公开的数据显示,截至2018年11月30日,在29例入组受试者中有7例部分缓解,整体回应率为24%(6名受试者仍在治疗中)。该数据显示CS1001在多种实体瘤和淋巴瘤中均观察到持久的抗肿瘤活性。
即将在ESMO2019年年会上公布的试验最新数据包括CS1001-101在Ia/Ib期研究中的安全性数据,以及Ib期研究在胃癌、食管癌、MSI-H肿瘤及胆管癌中的有效性数据。值得一提的是,此前已公开的数据显示,CS1001整体安全性与耐受性良好,在多种类型的肿瘤中都能观察到持久的抗肿瘤活性。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.